MedImmune, Inc. has signed a license agreement with Japan Tobacco, Inc. (JT) with the intent to develop a monoclonal antibody (MAb) targeting pathways within the CD28 receptor family for treatment of certain inflammatory diseases. MedImmune will initially focus on developing the current lead antibody to inhibit a receptor believed to play a key role in controlling adaptive immune responses, called inducible-costimulator (ICOS), and thereby regulate T-cell dependent activation of B cells. Inappro...